Pediatric & Adult
55 Walls Dr., Fairfield, (203) 259-7070
500 Monroe Tpk, Monroe, (203) 445-1960
Dr. Kenneth Backman, Dr. Irena Veksler, and Dr. Katherine Bloom
Accidental exposures to peanut allergens in children are more likely to occur at home than at schools, and most events are managed inappropriately, according to study results. “We discovered that children are most at risk of exposure in their own homes,” Sabrine Cherkaoui, MD, division of allergy and clinical immunology, University of Montreal, said in a press release. “Furthermore, when children do have a moderate or severe reaction to an exposure, parents and medical professionals often do not know how to react appropriately.”
Cherkaoui and colleagues recruited 1,941 children with peanut allergy from two hospitals and allergy advocacy organizations between 2004 and 2014. Patient demographics, history of atopy and initial reaction to peanut were collected through questionnaires, and accidental exposures (AEs), including food ingested, signs, symptoms, location and treatment, were recorded. Five hundred and sixty-seven AEs occurred in 429 patients across 4,589 patient-years for an annual incidence rate of 12.4%. Initial reactions to peanut were considered moderate (50.1%), mild (26.3%) and severe (11.3%).
Thirty-seven percent of AEs occurred at the child’s home, 14.3% occurred at a relative or friend’s house, 9.3% occurred at a restaurant, and 31.6% took place at unknown locations. Exposures at school were minimal: 4.9% occurred at schools prohibiting peanut, and 3% took place at schools that allowed peanut. No epinephrine was administered to 36.5% of participants with mild AEs, 25.6% of participants with moderate exposures and 14.1% of participants with severe exposures. The researchers said longer disease duration, likely due to adjustments made over time, reduced the risk for an AE (adjusted HR = 0.9; 95% CI, 0.88-0.93).
“The most significant finding of this study is the discovery that most moderate and severe accidental exposures are managed inappropriately by caregivers and physicians,” Cherkaoui said in the release. “We believe that more education is required on the importance of strict allergen avoidance and the need for prompt and correct management of anaphylaxis.”
From: Cherkaoui S, et al. Clin Transl Allergy. 2015;doi:10.1186/s13601-015-0055-x.
Dr. Katherine Bloom of Allergy & Asthma Care of Fairfield County comments: This is an interesting study that points out that accidental exposures can occur anywhere, particularly in the home. It is critically important that all patients/families have a written food allergy action plan that they have reviewed in advance."
The time a mother spends breast-feeding her child has no impact on the development of allergy sensitization in children at high risk for developing allergies, according to recent study results.
“Our thorough analyses have shown no effect of breast-feeding on the development of sensitization. This is contrary to the general opinion and current health recommendations,” Ea Cecilie Jelding-Dannemand, MSc, of the University of Copenhagen, and colleagues wrote. “This perception of breast-feeding as an important protection against allergy might cause mothers of children who are at high risk of allergy-associated diseases to feel guilty and distressed if they are not able to breast-feed exclusively for the recommended period of time.”
The researchers analyzed the data of 335 children from the Copenhagen Prospective Study on Asthma in Childhood 2000 birth cohort from August 1998 to December 2001. The children were born to mothers with a history of asthma. The researchers’ objective was to assess the effects of the duration of exclusive breast-feeding on the development of sensitization in preschool children.
Researchers observed no link between duration of breast-feeding and sensitization at 7 years based on skin prick test responses or specific immunoglobulin E levels during the study period. There also was no relation between duration of exclusive breast-feeding and outcomes in children aged 7 years such as eczema, asthma, and allergic rhinitis.
“This information should be communicated to the public, moderating the general recommendation of breast-feeding based on the lack of evidence for any protective effect against allergy in at-risk children,” the researchers wrote. From the Journal of Allergy and Clinical Immunology - Jelding-Dannemand E, et al. J Allergy Clin Immunol. 2015;doi:10.1016/j.jaci.2015.02.023.
Dr. Kenneth Backman of Allergy & Asthma Care comments: "While the many benefits of breast-feeding are well-known, there has been conflicting evidence of its effects on the development of allergies in infants. This study is reassuring in that it shows that duration of breast-feeding is not related to the subsequent development of allergies. For many reasons, it is best if mothers breastfeed for up to a year if possible, but they should not feel that they have increased their child's risk of allergies if they must stop nursing sooner."
The American Academy of Allergy, Asthma and Immunology is calling for the more frequent use of penicillin skin testing to slow the development of antibiotic resistance, according to a press release. An allergy to penicillin, which is reported by approximately 10% of the U.S. population, is linked with an unrecognized hazard, which is receiving alternative antibiotics when penicillin would usually be the drug of choice. The problem with receiving alternative antibiotics, according to the release, is that they have been linked with higher costs, greater risk for adverse effects, longer hospital stays and encouraging resistant bacterial strains.
Almost nine out of 10 people with a suspected penicillin allergy have negative penicillin skin testing and can receive penicillin safely. “Without such testing, there is an unrealized opportunity to improve healthcare outcomes and reduce rising rates of antibiotic resistance,” Robert F. Lemanske, Jr., MD, FAAAAI, president of the American Academy of Allergy, Asthma, and Immunology said in the release. “Allowing many people to return to using penicillin antibiotics should slow the development of antibiotic resistance.”
The statement comes days after a 5-year strategy was released by the White House to combat antibiotic resistance nationally.
Dr. Irena Veksler of Allergy & Asthma Care of Fairfield County, comments: "We have long known that most patients with a history of reaction to penicillin antibiotics, such as amoxicillin, will actually be able to tolerate penicillin. Penicillin skin testing is a quick, safe, effective way to determine who is not actually allergic, and allow patients to take safer and more targeted antibiotic therapy when needed. This will reduce the use of newer, broad spectrum antibiotics, and slow the development of resistance."
HOUSTON, TX – The first ever published data from the highly anticipated Learning Early About Peanut (LEAP) study offers proof that early introduction of peanuts may offer protection from the development of peanut allergies. The study was led by Professor Gideon Lack at King’s College London. “We believe the results from this trial are so compelling, and the problem of the increasing prevalence of peanut allergy so alarming that new guidelines should be forthcoming very soon,” Hugh A. Sampson, MD, FAAAAI, noted in an accompanying editorial. Sampson is a past-president of AAAAI and current Director of the Jaffe Food Allergy Institute with the Icahn School of Medicine at Mount Sinai.
Lack and the LEAP study team randomly assigned 640 infants with severe eczema, egg allergy, or both, to either consume or avoid peanuts until 60 months of age. Additional clusters were identified in the cohort: children with sensitivity to peanut extract and children without sensitivity (as determined by skin prick tests). Remarkably, the overall prevalence of peanut allergy in the peanut-avoidance group was 17.2% compared to only 3.2% in the consumption group. The prevalence of peanut allergies in children with negative skin prick tests early in life was at 13.7% in the avoidance group and 1.9% in the consumption group. Similarly, children already sensitive to peanuts reflected a 35.3% prevalence of peanut allergy in the avoidance group, compared to only 10.6% in the consumption group.
“Early consumption is effective not only in high-risk infants who show no sensitivity to peanuts early on, but it is also effective in infants who already demonstrate peanut sensitivity,” first author George Du Toit, MB, BCh, also from Kings College London explained. While additional questions remain, researchers now wonder if the LEAP study – which has demonstrated that the early introduction of peanut dramatically decreases the risk of developing a peanut allergy by a staggering 70-80% – should prompt a change in food allergy guidelines.
“There appears to be a narrow window of opportunity to prevent peanut allergy,” says Lack. “As soon as infants develop the first signs of eczema or egg allergy in the first months of life, they should receive skin testing to peanut and then eat peanut products either at home if the test is negative or first under clinical supervision if the test if positive. Infants without such symptoms should be fed peanut products from four months of life.” Lack added that this advice applies to children in countries where peanut allergy is a problem and cautions that infants should not be fed whole peanuts because of the risk of choking.
The “Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy” was published in The New England Journal of Medicine and presented at a Keynote address for the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston. Funding for the LEAP study was provided by the National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy Research & Education (FARE).
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "Previous observational studies have suggested that early introduction may be better than delayed introduction. This is the first randomized, prospective study to show that early introduction of peanut can help prevent a peanut allergy. This is groundbreaking research that will likely change the advice we give to patients daily."
The World Allergy Organization has released conditional guidelines for the use of probiotics during pregnancy, breast-feeding and infancy to prevent allergic diseases. International clinicians and researchers gathered to develop recommendations about the use of probiotics in the prevention of allergy, and they issued the suggestions after reviewing randomized controlled trials of probiotics.
Alessandro Fiocchi, MD, director of allergy at the Pediatric Hospital Bambino Gesù in Rome, and colleagues issued three conditional recommendations for using probiotics:
•in pregnant women at high risk for allergy in their children;
•in women who breast-feed infants at high risk for developing allergy; and
•in infants at high risk for developing allergies.
While the panel did not find sufficient evidence to indicate probiotic supplements reduced the risk for developing allergy in children, the panel wrote that there is a likely benefit from using probiotics in the prevention of eczema.
Question 1: In determining if probiotics should be used by pregnant women, the researchers analyzed eight reviews and 21 randomized controlled trials (RCTs). Fifteen of the studies measured and reported development of eczema in children. The risk for eczema was reduced in children whose mothers received probiotic during pregnancy compared with placebo (RR = 0.72; 95% CI, 0.61-0.85). Development of asthma or wheezing was reported in eight studies and did not vary between the probiotic and placebo (RR = 0.93; 95% CI, 0.76-1.15).
The panel acknowledged the use of probiotics during pregnancy will most likely be determined by women’s preferences. “We agreed that the values and preferences of women regarding the use of probiotics during pregnancy are likely to depend on cultural and socioeconomic background,” the panel wrote. The European Academy of Allergy and Clinical Immunology (EAACI) Food Allergy and Anaphylaxis Guidelines states there is no evidence to suggest women modify their diet or take supplements during pregnancy to prevent the development of food allergy.
Question 2: The panel asked if women who breast-feed should or should not use probiotics. Thirteen RCTs were analyzed to determine a conditional recommendation to use probiotics if the child is at great risk for developing allergy. The use of probiotics during breast-feeding reduced the rate of eczema in infants when compared with placebo (RR = 0.61; 95% CI, 0.5-0.64). But, there is some uncertainty because the analyzed research also included studies where the mothers took probiotics during pregnancy and the infants also were actively taking probiotics. The EAACI Food Allergy and Anaphylaxis Guidelines indicate there is no evidence to suggest women who breast-feed should take any supplements to prevent food allergy in their children.
Question 3: The panel asked if probiotics should be administered to healthy infants. The panel analyzed five reviews and 23 RCTs and suggested using probiotics in infants at risk for allergy. When given to infants, probiotics decreased the risk for developing eczema compared with placebo (RR = 0.81; 95% CI, 0.7-0.94). However, there was no indication probiotics affected the development of allergic rhinitis in children (RR = 0.83; 95% CI, 0.39-1.79). Although the panel suggested the use of probiotics during infancy, there was some uncertainty as to when they should be initiated. “If probiotics are used in infants, it is not clear when they should be started and how long they should be used,” the panel wrote.
Dr. Irena Veksler of Allergy & Asthma Care of Fairfield County comments: "There has been mixed data on the benefit, if any, of probiotics in preventing or controlling allergic disease. While probiotics certainly have other benefits, it is still unclear if they are beneficial in allergies. Further studies are needed."
Long-term and/or high-dose use of a class of medications used for hay fever, depression and other ills has been linked in a new study to a higher risk of dementia. The drugs — called anticholinergics — include nonprescription diphenhydramine (Benadryl) and tricyclic antidepressants like doxepin (Sinequan). This class of medications also includes older antihistamines like chlorpheniramine (Chlor-Trimeton) and “antimuscarinic” drugs for bladder control, such as oxybutynin (Ditropan).
However, the study could only point to an association between long-term or high-dose use of these drugs and a higher risk of dementia, it could not prove cause-and-effect. Also, the relationship “did not occur at the lowest dosage range but did occur at higher dosages used long-term,” said one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox Hill Hospital in New York City. He was not involved in the new study. Manevitz also stressed that consumers “should not abruptly stop any current medication treatment but rather should first consult with their physician.”
The new study was led by Shelly Gray of the Group Health Research Institute-University of Washington. Her team explained that the anticholinergic class of medications work by blocking a neurochemical called acetylcholine, in both the brain and body. Manevitz noted that people “suffering from Alzheimer’s disease typically show a marked shortage of acetylcholine.”
The new study tracked outcomes for more than 3,500 seniors who were followed for more than seven years. Gray’s group found that people who took at least 10 milligrams per day of Sinequan, 50 mg per day of Benadryl, or 5 mg per day of Ditropan for more than three years were at greater risk for developing dementia. Manevitz noted that occasional use of these medications did not seem to be tied to a rise in dementia risk. “The risk of dementia was due to a cumulative total of exposure, not to an acute short course of treatment,” he said.
And, Gray said in an institute news release, “Older adults should be aware that many medications — including some available without a prescription, such as over-the-counter sleep aids — have strong anticholinergic effects. And they should tell their health care providers about all their over-the-counter [drug] use,” she added. However, “no one should stop taking any therapy without consulting their health care provider,” said Gray, director of the geriatric pharmacy program at the University of Washington’s School of Pharmacy. Instead, “health care providers should regularly review their older patients’ drug regimens — including over-the-counter medications — to look for chances to use fewer anticholinergic medications at lower doses,” she advised.
The study, published Jan. 26 in JAMA Internal Medicine, is the first to link higher use of anticholinergic medications to increased risk of dementia, the researchers said. It is also the first to suggest that the dementia risk associated with these drugs may not be reversible even years after people stop taking them. Manevitz called the new study “well designed,” and said the reversibility issue is a troubling one. “The general view has been that mild cognitive impairment is reversible in discontinuation of anticholinergic medication therapy,” he said, but this study seems to find otherwise.
According to Manevitz, “we need to educate patients and their families about over-the-counter medicines and alternative therapies. Also, elderly people in nursing homes tend to have a long list of medicines that need to be reviewed periodically for need to continue, interactions and redundancy.” He believes doctors should think about substitutes for anticholinergics when possible, prescribe the lowest dose possible, and stop the medication as soon as is medically advisable.
Gray offered similar advice. “If providers need to prescribe a medication with anticholinergic effects because it is the best therapy for their patient, they should use the lowest effective dose, monitor the therapy regularly to ensure it’s working, and stop the therapy if it’s ineffective,” she suggested. She said that substitutes are available for some anticholinergic drugs, including a selective serotonin re-uptake inhibitor (SSRI) antidepressant like citalopram (Celexa) or fluoxitene (Prozac) for depression, or a second-generation antihistamine such as loratadine (Claritin), fexofenadine (Allegra), or cetirizine (Zyrtec) for allergy relief.
Dr. Katherine Bloom of Allergy & Asthma Care of Fairfield County comments: "In recent years we've discouraged the use of older, first-generation antihistamines, in favor of newer, second generation agents. This is due to the increased risk of side effects including drowsiness and dry mouth/ eyes (from the anticholinergic effects.) This study gives one more reason to avoid the older antihistamines, though of course further studies are necessary to confirm the findings."
Prenatal and early-life exposure to antibiotics does not seem to cause asthma in children, according to large new study. "Our results indicate that there doesn't seem to be a causal link between antibiotic treatment during pregnancy or early in life and childhood asthma," lead author Dr. Anne Ortqvist of the Karolinska Institute in Stockholm told Reuters Health by email. "Instead, we suggest that factors that are shared within families, such as genetic predisposition to respiratory infections and asthma, consultation patterns or other home and environmental factors, together with confounding by respiratory infections, have biased previous results."
Given that the rise in antibiotic use occurred in tandem with increases in asthma prevalence in children, several observational studies have been conducted to evaluate whether the two are related, but results have been mixed, Dr. Ortqvist and her team write in their report, published online November 28 in BMJ. In the new study, the researchers sought to account for familial factors by using sibling controls. To address the possibility of confounding by indication and reverse causation, they examined whether specific antibiotic types were linked to asthma. They looked at more than 493,000 children born in 2006-2010, and identified nearly 181,000 who were eligible for sibling analyses.
While prenatal exposure to antibiotics overall was linked to an increased risk of asthma (hazard ratio, 1.28), sibling analyses did not find an association (HR, 0.99), the researchers found. The risk associated with asthma was more pronounced when looking at antibiotics used to treat respiratory infections (HR, 4.12) versus antibiotics used to treat urinary tract or skin infections in children (HR, 1.54). However, sibling analyses reduced the association for exposure to antibiotics for respiratory infections (HR, 2.36), and there was no significant association between the use of antibiotics for urinary tract or skin infections and asthma risk (HR, 0.85).
"Our study suggests that antibiotics do not cause asthma, however, considering the threat of antibiotic resistance worldwide it is of great importance that antibiotics are used carefully," Dr. Ortqvist said. "So, if clinicians' use of antibiotics should change in any way that would be to consider the necessity of treatment with antibiotics for each patient one more time before prescribing it." She added: "We would like to emphasize the importance of correctly diagnosing children with respiratory symptoms, where suspected symptoms of asthma should be separated from respiratory infections, and treated according to guidelines. Also, as the majority of respiratory infections in young children are caused by viruses, the need of treatment with antibiotics in these children may be questioned."
Dr. Ortqvist said she and her colleagues are planning to use Swedish population-based data to investigate whether early antibiotic exposure is associated with other childhood illnesses.
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "There have been many studies trying to determine the causes and risk factors for childhood asthma. While early life antibiotics have been implicated in some smaller studies, this well designed study did not identify an association. Many studies continue to try to identify the cause of the increase in asthma and allergies in children and adults."
A chemical called methylisothiazolinone, used as a preservative in many baby wipes, soaps, and other household products, is responsible for many cases of contact dermatitis, which can cause eczema of the hands and other areas. The compound, often referred to as MI, was named the 2013 allergen of the year by the American Contact Dermatitis Society. See this interesting article from the New York Times.
This contact allergy can be detected through patch testing. If you have eczema affecting your hands or other areas and suspect a contact allergy, Allergy & Asthma Care of Fairfield County can perform patch testing for the common contact allergens. Please contact our office at 203-259-7070.
Dr. Irena Veksler of Allergy and Asthma Care of Fairfield County comments: "This contact allergen has been on our patch test panel for some time, but it has been an underappreciated cause of contact allergies and hand eczema. Hand eczema is often due to irritants and not allergens, but it is always important to rule out contact allergens as a cause."
A recent study by a Japanese institute found that consistently using emollients on newborn babies can prevent atopic dermatitis (eczema) and food allergies later in life. Emollient therapy with newborn babies is an inexpensive and easy way to prevent and treat the increasing global epidemic of eczema and prevent food allergies.
The National Center for Child Health and Development in Tokyo conducted a small-scale study. Researchers found that using emollients regularly during the first few weeks of life can help the immune system and keep it functioning properly. Researchers studied two groups of newborns. One group used emollients regularly on the babies. Another group had no treatment. The researchers studied 118 newborns for 32 weeks.
Results showed 19 babies developed atopic dermatitis (eczema) in the group using regular emollients. 28 babies developed atopic dermatitis (eczema) in the group using no treatment. This is the first study of it’s kind worldwide and suggests that using emollient therapy can reduce the risk of developing atopic dermatitis (eczema) by 30 percent.
The National Center for Child Health and Development stated in a recent press release that emollient therapy prevents the skin from drying out and cracking. Dry cracked skin allows irritants to enter the body exposing immune cells to these irritants. The immune system then boosts the body’s production of antibodies to combat these irritants, resulting in over-production. This over-production of antibodies causes the symptoms of allergy such as atopic dermatitis (eczema) and allergies and food allergies.
Toru Sato, the center’s spokesman, stated “It was known before that dry skin would cause eczema. One of the achievements of this study is that we came up with clear figures for the probability of developing eczema. Researchers are now looking at why some babies in the group still went on to develop eczema. Another important point is that the study suggests atopic skin problems could be linked to other allergic reactions, such as asthma and hay fever, that may appear later in life.”
How to apply this study? If you have a young baby, applying an emollient or moisturizer after their bath is a good way to keep their skin soft and supple. Keeping newborn skin healthy is easy and may prevent them from developing eczema, allergies and food allergies.
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "We've long known that moisturization is a critical component of eczema skin care, and that good skin care can help prevent eczema flares. There is now evidence that moisturization in early life can actually prevent eczema. We look forward to more studies on this topic."
Babies exposed to traces of peanut protein in house dust may have a higher risk of peanut allergy researchers say. In a new UK study, published online in the Journal of Allergy and Clinical Immunology, exposure to peanut protein in house dust doubled the chance of having a peanut allergy. In children who have eczema, the risk of having peanut allergy was even higher.
Around 2% of school children in the UK are allergic to peanuts. Researcher Helen Brough, from the department of paediatric allergy at King's College London and colleagues from the University of Manchester and the University of Dundee , note that eczema "is often cited as the first step in the allergic march." They say that exposure to peanut proteins in dust through eczema-inflamed skin can trigger a peanut allergy. How peanut allergies develop is not yet clear, says Dr Carla Davis, a specialist in children's allergies at Texas Children's Hospital in Houston in the US. There is still plenty of controversy in the field, she says. For instance, some researchers are testing a "patch" for people who already have a peanut allergy that would introduce the allergen through the skin to build tolerance. That seems to contradict the findings in this study, she says.
The researchers found out how much peanut protein infants were exposed to by measuring dust vaccuumed from the patients' living rooms. They studied 359 children who had a high risk of developing a peanut allergy because they were already allergic to cow's milk or eggs, or had moderate or severe levels of eczema and had allergies to those foods. "This study adds to the growing body of evidence that exposure to peanut via a damaged skin barrier [as in eczema] may increase the risk of peanut allergy,” Helen Brough says in a news release.
Professor Gideon Lack, senior author from the Department of Paediatric Allergy, King's College London, adds: "This is further evidence for the dual-allergen-exposure theory which suggests food allergies develop through exposure to allergens via the skin, likely through a disrupted skin barrier, whilst consumption of these food proteins early in life builds up tolerance in the body. Previous guidelines recommending that mothers should avoid peanuts during pregnancy and breastfeeding have now been withdrawn. Ongoing studies at King's aim to find if exposure to solids in early infancy might actually help to prevent allergies. It may be that the timing and balance of skin and oral exposure to a particular food early in life determines whether a child develops an allergy or tolerance to that food."
Several people involved in the study report receiving support from, or consulting for, pharmaceutical and other companies and organisations, including the US National Peanut Board.
Dr. Irena Veksler of Allergy & Asthma Care of Fairfield County comments: "It has long been known that patients with eczema are at increased risk of food allergies. This study identifies one possible cause of this increased risk, and suggests a possible cause of peanut allergy in particular. More studies are definitely needed."
Eosinophilic esophagitis (EoE) is an emerging allergic disorder predominantly triggered by food allergens. Several dietary interventions have been evaluated in adults so far. Based on amino acid-based formulas, elemental diet is the most effective, but is also impractical, whereas elimination diet based on skin testing has shown suboptimal cure rates (26%-36%). An empiric six-food group elimination diet (SFGED), prospectively evaluated in unicenter studies, has achieved remission in over 70% EoE patients. Still, the majority (65%-85%) of SFGED responders have just one or two causative foods identified after six food-group challenges and endoscopies, so some dietary restrictions and subsequent endoscopies after food challenge may be unnecessary.
Now, in a study recently published in The Journal of Allergy and Clinical Immunology, Javier Molina-Infante and colleagues present the results of the first prospective multicenter study on empiric elimination diet for EoE, evaluating a simplified four-food group elimination diet (FFGED) (dairy products, wheat, egg and legumes) for adult EoE.
The efficacy of this six week FFGED was evaluated in 52 consecutive patients from four Spanish hospitals. In those unresponsive to FFGED, a rescue SFGED was proposed. Among patients responsive to a FFGED, 78% completed the individual food reintroduction process.
The study shows 54% of adult EoE patients achieve clinicohistological remission on an empiric FFGED; in addition, almost a third of non-responders to FFGED could be effectively rescued with a SFGED, coming to an overall effectiveness of 72%. Therefore, 3 out of every 4 adult patients achieving remission on a SFGED may achieve it on a FFGED, a less restrictive dietary intervention that requires fewer endoscopies and shortens the food reintroduction process. After food reintroduction, all FFGED responders had just 1 or 2 food triggers identified. The most common food triggers were cow´s milk (50%), egg (36%) and wheat (31%), with milk being the only causative food in 27% of adult patients. Results were consistent among the four participating centers.
This study underscores the general applicability of dietary interventions for adult EoE in clinical practice. This multistage, empiric, dietary approach (FFGED followed by SFGED) may be recommended to simplify dietary management for EoE patients, since a FFGED is a simpler, cheaper and less inconvenient initial dietary intervention to screen a majority of EoE patients with one or two food triggers.
(from AAAAI.org website) For more info on eosinophilic esophagitis, click here
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "Eosinophilic esophagitis is a relatively newly identified disorder about which we continue to learn more. Food elimination diets have clearly been very effective in children, but in adults results have been mixed. This study demonstrates that food elimination diets can be quite helpful in adults, even while making them easier by reducing the number of foods avoided. Due to the difficulty in eliminating even this smaller number of foods, many adults choose to pursue swallowed "inhaled" steroids, which are highly effective."
A study in the Annals of Allergy, Asthma, and Immunology examined the effects of dairy intake during pregancy (Miyake Y. Ann Allergy Asthma Immunol. 2014;113:82-87.):
Higher maternal intake of total dairy products, cheese, yogurt and calcium during pregnancy was associated with a reduced risk for infantile eczema, asthma and atopic eczema in children, according to study results.
Researchers in Japan studied 1,354 mother-child pairs (mean maternal age, 31.5 years) to determine the association between maternal consumption of dairy foods, calcium and vitamin D during pregnancy and childhood allergic disorders in children aged 23 to 29 months. A diet history questionnaire was administered between April 2007 and March 2008 to determine maternal intake during pregnancy. International Study of Asthma and Allergies in Childhood criteria defined wheeze and eczema, while a questionnaire completed by mothers determined physician-diagnosed asthma and atopic eczema.
Reduced risk for infantile eczema was significantly associated with higher maternal intake of total dairy products (adjusted OR between extreme quartiles, 0.64; 95% CI, 0.42-0.98). A reduced risk for physician-diagnosed infantile asthma correlated with a greater maternal intake of cheese (aOR=0.44; 95% CI, 0.18-0.97).
Yogurt (aOR=0.49; 95% CI, 0.2-1.16) and calcium consumption (aOR=0.34; 95% CI, 0.12-0.84) during pregnancy showed inverse associations with physician-diagnosed infantile atopic eczema. A significant association existed between maternal vitamin D consumption during pregnancy and infantile eczema (aOR=1.63; 95% CI, 1.07-2.51).
“The current prebirth cohort study in Japan suggests that higher maternal intake of total dairy products, cheese, yogurt and calcium during pregnancy may reduce the risk of infantile eczema in the last 12 months, physician-diagnosed asthma, physician-diagnosed atopic eczema, and physician-diagnosed atopic eczema, respectively,” the researchers concluded. “Higher maternal intake of vitamin D during pregnancy may increase the risk of infantile eczema in the last 12 months.
“Further well-designed prebirth cohort studies with accurate assessment of dietary habits during pregnancy and childhood allergic disorders are required to confirm these findings.”
Dr. Katherine Bloom from Allergy & Asthma Care of Fairfield County comments:"While this study needs to be confirmed, it is encouraging that something as simple as increasing the intake of dairy products may have the potential to help prevent eczema and allergic diseases in children."
Posted on September 17, 2014 | Permalink
| | |
The American College of Allergy, Asthma and Immunology has warned parents of children with asthma and allergies to be aware of their child’s symptoms regarding enterovirus D68.
“If your child seems to be struggling to breathe and their normal asthma medications aren’t working, get him or her to the emergency department as soon as possible,” allergist Bradley Chipps, MD, a spokesman for theACAAI, said in a press release. “The most important thing is for every child with asthma to have a personalized action plan, created with his or her allergist, [which] helps quickly identify when a child … needs immediate, emergency attention.”
Although enterovirus D68 symptoms first appear as a common cold, they can quickly move to more severe respiratory symptoms including wheezing and difficulty breathing, the release said.
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "While many children affected by enterovirus D68 may develop an illness no worse than the common cold, this virus can cause very serious and sudden respiratory complications. If your child becomes ill and develops asthma symptoms that are not quickly and easily reversed with the quick relief inhaler (albuterol or levalbuterol,) contact your physician immediately. If your child is in distress or struggling to breathe, do not hesitate to seek emergency care."
Posted on September 17, 2014 | Permalink
| | |
Surveyed pediatric patients with food allergies, and accompanying parents and families did not always carry self-injectable epinephrine, according to recent survey results. Researchers surveyed patients or families of patients with a documented history of food allergy during a 30-day follow-up period at the Nationwide Children’s Hospital outpatient allergy clinic, Columbus, Ohio. Age, previously diagnosed food allergies, diagnostic method, symptoms associated with previous food reactions and comorbid atopic conditions were collected. Information about carrying epinephrine auto-injector also was requested.
Thirty-five surveys were returned, and 20% of respondents reported a previous allergic reaction to food requiring treatment with self-administered epinephrine. Twenty-nine percent of those respondents had self-injectable epinephrine with them during the survey. Of the patients with self-injectable epinephrine during the survey, almost 90% had the weight-appropriate dose, but almost 50% of the auto-injectors were expired. While 60% of patients endorsed always carrying self-injectable epinephrine, only 40% of patients had the product available during the survey.
Nearly 90% of respondents reported peanut allergies, but only 43% of the patients had self-injectable epinephrine available. Accidental exposure to a food allergen was reported by 30% of patients, but only one-third of them had epinephrine available during the survey. Availability in other places such as the home, car or school, expiration of previous prescription, cost, and not knowing that it should always be carried were reasons given for not having self-injectable epinephrine with them.
“It will be necessary to continue to foster relationships with patients and their families, teachers, school administrators and staff, and community leaders to provide comprehensive food allergy care,” the researchers concluded. “Moreover, we must routinely evaluate our educational methods with respect to epinephrine efficacy and access; if these methods are ineffective it will be necessary to improve them.”
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "We have long known that one of the strongest risk factors for fatality in patients with food allergy is the absence of immediately available epinephrine. While prescribing of epinephrine autoinjectors is on the rise, unfortunately many patients with food allergy do not carrry them at all times. This is an important issue that education and frequent reminders can hopefully help overcome."
MILWAUKEE, WI – Warmer weather means more time outdoors, but spending time outside brings with it the chance of coming in contact with stinging insects, which are among the most common triggers of a serious, life-threatening reaction called anaphylaxis. However, a new paper in The New England Journal of Medicine cites venom immunotherapy as the best treatment option for people who are allergic to stinging insects as it can reduce the risk of a future severe reaction to less than 5%.
Written by American Academy of Allergy, Asthma & Immunology (AAAAI) Executive Vice President Thomas B. Casale, MD, FAAAAI, and A. Wesley Burks, MD, FAAAAI, a past President, the paper follows the case of a 24-year-old woman who was stung while drinking soda at a picnic. The woman began experiencing symptoms indicative of anaphylaxis minutes after being stung, including swelling of the lips, light-headedness, difficulty swallowing and hives. She was transported to a local emergency room and treated with epinephrine. After being observed for several hours, she was discharged and given autoinjectable epinephrine.
“As far as long-term therapy for people with stinging insect allergy, avoiding exposure to these insects is key, but the only treatment option that will actually prevent life-threatening anaphylactic reactions is venom immunotherapy,” said Dr. Casale.
Patients who have experienced a severe allergic reaction to an insect sting should see an allergist/immunologist, who can provide appropriate testing and determine if venom immunotherapy is the right treatment option. Venom immunotherapy is given in the form of shots, and about 80 to 90% of patients who receive it for 3 to 5 years do not have a severe reaction to a future sting.
“The other important thing to keep in mind is that patients with venom-specific IgE who have had a severe allergic reaction are at higher risk of having another severe allergic reaction,” explained Dr. Burks. “It is imperative for these individuals to carry autoinjectable epinephrine and know how to use it in an emergency.”
Epinephrine is the first-line treatment for anaphylaxis. In fact, the AAAAI recently released a second list for the ABIM Foundation’s Choosing Wisely® initiative that included an item highlighting the importance of epinephrine because data indicate that antihistamines are overused as the first-line treatment of anaphylaxis. Overuse of antihistamines, which do not treat the cardiovascular or respiratory symptoms of anaphylaxis, can delay treatment with epinephrine. Fatalities during anaphylaxis have been associated with delayed administration of epinephrine. Anyone who believes they are having an anaphylactic reaction should use autoinjectable epinephrine and seek medical attention immediately.
More information on stinging insect allergy, anaphylaxis and immunotherapy is available at the AAAAI website, www.aaaai.org
A recently published multi-center study found that supplemental vitamin D did not help patients with low vitamin D blood levels and symptomatic asthma. The trial, funded by the National Heart Lung and Blood Institute, failed to demonstrate any benefit of vitamin D on the primary measure - time to first treatment failure – or on eight of nine secondary measures.
“These findings do not support a strategy of therapeutic Vitamin D3 supplementation in patients with symptomatic asthma,” wrote the authors, who included Richard Martin, MD, chair of medicine at National Jewish Health, and Michael Wechsler, MD, director of the asthma program at National Jewish Health.
Earlier studies had associated low vitamin D blood levels with more asthma symptoms and medication use, and with reduced response to the mainstay asthma medication, inhaled corticosteroids.
The Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial was conducted at nine academic medical centers participating in the NHLBI’s AsthmaNet clinical research network. It randomized 408 adults with low vitamin D and mild/moderate asthma to receive the inhaled corticosteroid ciclesonide supplemented with either high-dose vitamin D3 or placebo. Participants were then monitored over 28 weeks for the occurrence of worsening asthma.
Vitamin D3 supplementation did not reduce the proportion of participants who experienced at least one treatment failure (28 percent vs. 29 percent in placebo) or one exacerbation (13 percent vs. 19 percent) nor the overall exacerbation rate. More of the vitamin D treated patients were able to reduce their inhaled steroid dose by 75 percent compared to those treated with placebo (89 percent vs. 80 percent).
The findings were presented on May 18, 2014, at the American Thoracic Society annual meeting and concurrently published in the Journal of the American Medical Association.
Dr. Katherine Bloom of Allergy & Asthma Care of Fairfield County comments: "Much has been learned about the benefits of vitamin D over the past several years. There has been some preliminary evidence that vitamin D supplementation might benefit asthma patients, but this well-constructed study demonstrates minimal effect. More studies need to be performed, but at this time, we cannot recommend vitamin D supplementation in the treatment of asthma."
The FDA approved the ragweed allergy treatment Ragwitek, the third sublingual immunotherapy (SLIT) approval last month. The announcement followed that of Merck's other SLIT agent, the Timothy grass pollen allergy tablet Grastek, on Tuesday and that of Greer's multi-grass pollen immunotherapy tablet Oralair earlier in April. While under-the-tongue drops made off-label from subcutaneous allergy shot extracts have been used by some practitioners, no SLIT agents had been FDA approved before. The liquid extracts manufactured for injections have generally been too weak to have clinical effectiveness when administered sublingually, but the new sublingual tablets are high dose and are proven effective.
Ragwitek gained approval for treatment of short ragweed pollen-induced allergic rhinitis, confirmed by a positive skin test or in vitro testing for pollen-specific immunoglobulin-E antibodies, with or without conjunctivitis, in adults ages 18 through 65. That upper age limit had been the source of some dissension on the FDA advisory panel that recommended approval. The pivotal trials included no patients over age 51, so a few panel members felt the evidence wasn't sufficient for older patients.
The other two SLIT agents approved have gained an indication for pediatric use, but that wasn't sought or studied with Ragwitek. But the Ragwitek approval otherwise followed closely with that of the grass allergy SLIT agents. It was approved for once daily use starting 12 weeks before the start and continued through the offending pollen season, which typically runs from late summer to early fall. The first dose should be taken in-office and the patient observed for at least 30 minutes for potential adverse reactions.
The most common adverse reactions reported with Grastek and Ragwitek have been itching in the mouth and ears and throat irritation, but the drug carries a boxed warning of the risk of severe allergic reactions. Due to that risk, patients should be prescribed auto-injectable epinephrine and trained in its use.
Patients with severe, unstable, or uncontrolled asthma or a history of any severe systemic allergic reaction, eosinophilic esophagitis, or any severe local reaction after taking any SLIT agent shouldn't get Ragwitek.
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "This adds two more options to the new category of sublingual immunotherapy tablets, the first under-the-tongue allergen immunotherapy that has proven effectiveness to the satisfaction of the FDA. It is exciting to have this new treatment option available, and look forward to discussing this and other options with our patients."
The FDA has approved the first and only sublingual oral immunotherapy formulation, Oralair, a sublingual dissolving tablet for grass allergies in the United States.
Oralair (sweet vernal, perennial rye, Orchard, Timothy and Kentucky blue grass mixed pollens allergen extract, Greer/Stallergenes) is to be used as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin or blood testing for grass pollen-specific IgE antibodies for any of the five grass species contained in the product. It is indicated for patients aged 10 to 65 years.
“While there is no cure for grass pollen allergies, they can be managed through treatment and avoiding exposure to the pollen,” Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said in a press release. “The approval of Oralair provides an alternative to allergy shots that must be given in a health care provider’s office. Oralair can be taken at home after the first administration.”
The first dose would be administered at a doctor’s office. Data indicate that the drug be initiated 4 months before the expected onset of each grass pollen season and continued throughout the season. In clinical trials, Oralair was well-tolerated; the most common adverse events were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. The drug contains a black boxed warning due to the drug’s potential for anaphylaxis and severe laryngopharyngeal edema. Oralair is contraindicated (not recommended) in patients with severe, unstable, or uncontrolled asthma, or with a history of severe systemic or local reaction to sublingual allergen immunotherapy.
Merck and Danish partner ALK Abelló also are expected to launch their rival agent, Grastek, later this year, according to a press release. Oralair was first approved in the European Union in 2008 and is marketed in Canada, Australia and Russia to treat grass pollen allergy.
Dr. Irena Veksler of Allergy & Asthma Care of Fairfield County comments: "This is exciting as it represents the first FDA approved sublingual immunotherapy in the United States. While most studies have found that subcutaneous (injected) allergen immunotherapy is more effective than sublingual, this is an option for patients whose main allergen is grass pollen, and who desire a way to build their immunity to grass pollen without injections. While some practitioners in this country have offered sublingual drop immunotherapy, this has generally been at doses far too low to have any clinical effect. These grass pollen tablets, while less effective than injections, should provide significant improvement in symptoms."
Chronic urticaria (hives) can be a miserable experience for those that are afflicted. Many patients with this condition suffer from daily, very itchy hives that are difficult to control, often requiring multiple antihistamines and other medications to control their symptoms. For many of these patients, complete control is rarely if ever achieved.
There is now a new option available for the treatment of chronic urticaria - Xolair (omalizumab.) Xolair is a biologic medication originally developed to treat asthma, and it has turned out to be highly effective for many patients suffering from chronic hives. Xolair has now received FDA approval for the treatment of chronic hives. If you or a loved one suffers from chronic hives, please contact our office and schedule an appointment to review your options.
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "We've had success treating difficult-to-control asthma with Xolair, and in our office it has been a remarkably safe and well tolerated option. Chronic hives can often be much more difficult to control, and the ability to prescribe Xolair for this condition should greatly improve the lives of many of our patients."
Oral immunotherapy (OIT) for children's peanut allergy may be a safe and effective approach, a new study has shown. Findings from the phase 2 trial, published in the Lancet in January, add to accumulating evidence that children can gradually build tolerance by ingesting increasing amounts of peanut protein.
Previous results from small studies have suggested that peanut OIT might be an effective strategy for managing children with peanut allergy. However, until now, the approach had not been thoroughly evaluated in a sizable group of children. Therefore, the investigators designed a 2-step, randomized controlled crossover trial testing OIT in 99 children aged 7 to 16 years. Children with all levels of peanut sensitivity were included in the trial.In the first step, children were randomly assigned to 1 of 2 groups. One group received 26 weeks of OIT, which consisted of gradually increasing doses of peanut protein up to 800 mg daily. The other group was advised to avoid peanuts per usual, serving as controls. At the end of the 26 weeks, both groups underwent peanut challenge.
In the second phase, children in the control group were offered the 26-week OIT treatment followed by challenge. "OIT successfully induced desensitisation in most children within the study population with peanut allergy of any severity, with a clinically meaningful increase in peanut threshold," the researchers report. "Peanut OIT raises the reactive threshold at least 25-times so that 84–91% of participants can tolerate daily ingestion of 800 mg protein."
At the end of the first trial phase, 84% (95% confidence interval [CI], 70% - 93%) of the children in the active intervention group tolerated daily ingestion of 800 mg protein compared with none in the control group. In addition, 62% (95% confidence interval [CI], 45% - 78%) of the active intervention group had become desensitized, which was defined as having no reaction to ingestion of 1400 mg peanut protein (roughly equivalent to 10 peanuts). After the second trial phase, 91% (95% CI, 79% - 98%) of children who had been assigned initially to the control group were able to tolerate ingestion of 800 mg protein daily, and 54% (95% CI, 35% - 72%) had become desensitized. The authors point out that it would be unlikely for children to accidentally encounter 1400 mg of peanut protein.
About a fifth of the patients reported adverse reactions to OIT. However most were mild, with oral itching being the most common, occurring after 6.3% of doses (76 children). Gastrointestinal symptoms were also common, with 31 children reporting nausea, 31 reporting vomiting, and 1 reporting diarrhea. In addition, 41 children developed wheeze (0.41% of doses) and 1 child required intramuscular adrenaline. In an accompanying comment, Matthew J. Greenhawt, MD, from the University of Michigan Food Allergy Center, Division of Allergy and Clinical Immunology, Ann Arbor, stressed that although the results of the study are promising, more high-quality data are needed before recommending the therapy to all child and adolescent patients with peanut allergy.
"It is important to understand that OIT research cannot be rushed, and is years away from routine clinical use," Dr. Greenhawt notes. "Investigative groups need time to refine protocols, revalidate data, understand the mechanisms of OIT, and minimise adverse effects. This must be done without added pressure or heightened expectations to quickly produce a marketable therapy," he concludes.
Dr. Katherine Bloom of Allergy & Asthma Care of Fairfield County emphasizes "while this adds to the exciting research demonstrating effectiveness of oral immunotherapy, it is still too soon for this to be offered in the community. As Dr. Greenhawt notes, more research is needed before it would be appropriate to offer this in physicians' offices outside an academic clinical trial. We look forward to more research in this area."
Source: Medscape Medical News 1/29/14
Drug regulators in the European Union (EU) have recommended approving omalizumab ( Xolair, Novartis, Genentech) as an add-on therapy for patients with chronic spontaneous urticaria (CSU), the European Medicines Agency (EMA) announced today.
Omalizumab already is approved in the EU as an add-on therapy for allergic asthma. Yesterday the EMA's Committee for Medicinal Products for Human Use (CHMP) cleared the drug for patients 12 years of age and older with CSU who have not responded adequately to H1 antihistamine treatment.
The US Food and Drug Administration (FDA) okayed omalizumab as a stand-alone therapy for allergic asthma in 2003. Four years later, the agency added a boxed warning to the drug's label about the risk for life-threatening anaphylaxis. The FDA is weighing whether to follow CHMP's lead and approve the drug for CSU.
CHMP's recommendations on omalizumab and ustekinumab await a final decision from the European Commission, the executive branch of the EU.
From Medscape Medical News
Dr Kenneth Backman from Allergy & Asthma Care of Fairfield County comments: "Studies have demonstrated that Xolair can lead to dramatic improvement in patients with difficult-to-treat hives. The FDA is expected to approve Xolair for this condition soon, and we look forward to being able to offer this to patients. There are some insurance companies that already cover this for severe hives, so patients suffering from chronic hives should contact us for additional information."
A recent study published in the Journal of Allergy and Clinical Immunology (JACI) demonstrates that toddlers who are allergic to raw egg but can safely eat foods containing baked egg seem more likely to outgrow their egg intolerance by age 2.
"The findings show us that there are in general two types (of) patients with egg allergy, those who will outgrow the allergy in a few years and those who it will take longer to outgrow it," said Dr. Wesley Burks, who chairs the department of pediatrics at the University of North Carolina in Chapel Hill and was not involved in the study."The first group can be identified with the ability to consume baked-egg products and if they put these products in their diet they may outgrow the egg allergy sooner," Dr. Burks told Reuters.
The new work, led by Dr. Katrina Allen from the Royal Children's Hospital in Parkville, Victoria, Australia, was published online December 27 in the Journal of Allergy and Clinical Immunology.
To test for allergic reactions, Dr. Allen and her team administered prick tests to more than 5,100 one-year-olds. They then performed oral food challenges on those who responded, including raw eggs and a muffin containing baked egg, and followed up with baked-egg tests again when the children were two years old. They reported results for 140 children who completed follow-up. Nearly half the children (47%) outgrew their egg allergy by age 2. Statistical analysis revealed two significant predictors of persistent egg allergy: the baseline skin-prick test (adjusted odds ratio, 3.34) and egg specific serum IgE of 95% or greater positive predictive value (aOR, 29.46).
Another predictor was tolerance to baked egg. At baseline, 20% of the infants who reacted to raw egg also reacted to baked egg, and after adjustment for confounders these children were five times as likely to remain allergic through age 2 as were those who tolerated baked eggs (aOR, 5.27). "We believe our results will help decide which children should be entered into studies of oral immunotherapy for egg allergy," Dr. Allen said.
It's possible that eating baked eggs may improve tolerance. When infants who could eat baked egg at age 1 ate foods containing baked eggs five or more times per month they were three times more likely to tolerate raw egg at age 2 (OR, 3.51)." For families with children with egg allergy, this is a well done study to help them know that for many children with egg allergy, this allergy will be outgrown early in life. It also shows us that if a child can tolerate baked egg, then it is probably good for them to incorporate this into their diet," Dr. Burks says.
Dr. Katherine Bloom of Allergy & Asthma Care of Fairfield County comments: "Previous studies have demonstrated that patients with milk allergy are more likely to outgrow the allergy if they tolerate baked milk, and that ingestion of baked milk may lead to more rapid resolution of the allergy. This study demonstrates that the same appears to be true of egg allergy. Patients with these food allergies would benefit from allergy testing and possible in-office baked food challenges to determine whether they can eat these forms of the food and accelerate resolution of the allergy."
SOURCE: http://bit.ly/19EVBdX and Reuters.
J Allergy Clin Immunol 2013.
The following summary is taken from the American Academy of Allergy, Asthma, and Immunology website, www.aaaai.org.
Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often have uncontrolled symptoms despite the use of non-sedating H1-antihistamines at up to four times the standard dose. For those patients who remain symptomatic, other treatment options include H2-antihistamines, leukotriene receptor antagonists [LTRAs], dapsone, cyclosporine and methotrexate. However, there is a lack of high-quality clinical evidence to support their use, and immunosuppressants are potentially associated with severe adverse effects. In an original article in The Journal of Allergy and Clinical Immunology (JACI), Kaplan et al. present results from a randomized, double-blind, placebo-controlled study of omalizumab, an anti-immunoglobulin E monoclonal antibody approved as add-on therapy for inadequately-controlled moderate-to-severe allergic asthma and under investigation for use in refractory CIU/CSU.
The primary objective of the study was to assess the safety of omalizumab 300 mg administered at 4-week intervals in patients with CIU/CSU refractory to H1-antihistamines (including up to 4x approved dose) plus H2-antihistamines and/or LTRAs. Efficacy assessments included weekly itch severity score (key secondary endpoint), change from baseline in weekly urticaria activity score, weekly number of hives score, weekly size of largest hive score, health-related quality-of-life (Dermatology Life Quality Index), proportion of angioedema-free days, and proportion of patients who were completely hive- and itch-free.
During 24 weeks of treatment and a subsequent 16-week follow-up period, the incidence and severity of adverse events and serious adverse events were similar between omalizumab and placebo. There were no anaphylactic reactions, malignancies or deaths, and no new safety issues were identified. At Week 12, there was a greater improvement in weekly itch score in the omalizumab group, compared with placebo (-8.6 vs. -4.0; P<.001), with sustained benefit at Week 24 (-8.6 vs. -4.0; P<.001) (see figure). There were also significant improvements with omalizumab, versus placebo, for all other efficacy endpoints.
Overall, this study showed that omalizumab is well tolerated and effective in patients with symptomatic CIU/CSU despite multiple background therapy with H1-antihistamines and H2-antihistamines and/or LTRAs.
Dr. Irena Veksler of Allergy & Asthma Care of Fairfield County comments: "The study demonstrated that omalizumab (Xolair,) currently approved for moderate to severe asthma, can help control chronic hives of unclear cause (chronic idiopathic urticaria.) We currently await FDA approval of Xolair for this condition, and then will need to see how well insurance companies cover this very expensive treatment. We are hoping to have this treatment available for this frustrating condition."
Mothers' receipt of immunotherapy during pregnancy may reduce the risk of any type of allergy in offspring, according to a study presented at the annual meeting of the American College of Allergy, Asthma & Immunology, held from Nov. 7–12 in Baltimore.
Jay Lieberman, MD, from Le Bonheur Children's Hospital in Memphis, Tenn., and colleagues performed a pilot study to examine the correlation between immunotherapy in mothers and allergic disease status in offspring. One hundred forty-three women, aged 18–48 years, with a physician diagnosis of allergic rhinitis were surveyed to assess immunotherapy history and presence of allergic disease in their 277 biological children.
The researchers found that treatment with immunotherapy while pregnant was not associated with the prevalence of allergic disease in offspring in univariate analysis. However, after controlling for breastfeeding, gender, presence of older siblings, and father's allergic status, receipt of immunotherapy while pregnant correlated with a non-significant trend toward decreasing child allergy rates for any type of allergy (odds ratio, 0.84; 95% confidence interval, 0.38–1.84).
"More research is needed to understand if mothers can truly prevent allergies in their children by receiving allergy shots during or before pregnancy," Lieberman said in a statement. "However, these study results show there is a strong association which is very encouraging as allergists explore this possibility."
Dr. Kenneth Backman of Allergy & Asthma Care of Fairfield County comments: "This is provocative research that needs to be validated. We've long known that allergen immunotherapy is highly effective and is safe to receive during pregnancy. Now there is evidence that immunotherapy during pregnancy may actually benefit the unborn child. We look forward to additional research in this area."